Exosome Diagnostics and Therapeutics Market by Type (Diagnostics, Therapeutics), Product & Service (Instruments, Kits, Reagents), Source (Stem Cells, Blood, Blood Plasma, Urine), Application (Cancer, Musculoskeletal, CVD) - Global Forecast to 2032
The exosome diagnostics market is projected to grow from USD 59 million in 2024 to USD 2,347 million by 2029 at a CAGR of 108.9%. However, the candidates for exosome-based therapeutics are expected to be launched in the market from 2029 onwards. Thus, collectively exosome diagnostics and therapeutics market is expected to generate USD 59 million by 2024 and projected to reach USD 6,848 million in 2032 at a CAGR of 81.2%. Increasing number of clinical trials is expected to support the segment growth. Exosome-based therapies utilize vesicles released by cells to deliver therapeutic payloads. These vesicles offer advantages such as enhanced cargo bioavailability and the ability to cross biological barriers such as the blood-brain barrier. Despite these benefits, exosome therapies have not yet received regulatory approval. This is attributed to the challenges of standardizing exosome isolation and purification methods, scaling production, safety assurance, and regulatory processes. Companies such as Regeneus Ltd (Australia), CUREXSYS (Germany), and Direct Biologics LLC (US) are the key players in this segment that are focused on developing exosome-based therapeutics for clinical indications.
“Instruments & services segment is expected to grow at the fastest pace during the forecast period.”
Exosome characterization is done precisely through flow cytometry, nanoparticle tracking analysis, and ultracentrifugation in exosome diagnoses and treatments. The rising demand for exosome characterization & enrichment services is expected to support market growth. Some market players operating in the exosome diagnostics and therapeutics market also use their patented/proprietary technologies to offer end-to-end exosome services, including engineering, characterization, and purification. These players provide support services from a commercial viewpoint, targeted toward scalable exosome manufacturing and analysis from potential diagnostic samples such as blood, urine, and saliva.
“The urine source segment accounted for the largest share in the exosome diagnostics and therapeutics market in 2023.”
Rapid commercialization of urine sample-based diagnostic tests is set to drive market. Urinary exosomes, released by cells in the urine system, represent an emerging route for diagnosing and monitoring renal disorders. Their distinct characteristics, such as the capacity to shield their molecular cargo from degradation and contamination, make them primary candidates for renal dysfunction and structural injury biomarkers. The non-invasive method of urine collection and the stability and sufficiency of urinary exosomes highlight its potential for early disease detection and diagnosis.
“Cancer is expected to emerge as the dominant application segment in the exosome therapeutics market.”
Growing focus on oncology therapeutics is expected to propel the market growth. Exosomes also play a critical role in cancer therapy as carriers of therapeutic cargo, delivering drugs, RNA interference molecules, or immunomodulatory agents to target cancer cells. The University of Texas MD Anderson Cancer Center in Texas (US) is conducting clinical trials (NCT03608631) to study the optimal dosage effects and effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation. Despite these developments, challenges such as optimizing the exosome isolation technology and ensuring efficient delivery of therapeutic cargo to tumors are expected to hinder market growth during the forecast period.
North America dominates the global exosome diagnostics and therapeutics market throughout the forecast period.
The exosome diagnostics and therapeutics market is segmented into four regions: North America, Europe, the Asia Pacific (APAC), and the Rest of the World. As of April 2024, only one exosome-based diagnostic product has been approved and is available in the US. The US has thus emerged as a key revenue source for the global exosome diagnostics and therapeutics market, in turn making North America the dominant region in the market.
Breakdown of supply-side primary interviews by company type, designation, and region:
This report studies the exosome diagnostics and therapeutics market based on type, product & service, source, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total exosome diagnostics and therapeutics market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
.
“Instruments & services segment is expected to grow at the fastest pace during the forecast period.”
Exosome characterization is done precisely through flow cytometry, nanoparticle tracking analysis, and ultracentrifugation in exosome diagnoses and treatments. The rising demand for exosome characterization & enrichment services is expected to support market growth. Some market players operating in the exosome diagnostics and therapeutics market also use their patented/proprietary technologies to offer end-to-end exosome services, including engineering, characterization, and purification. These players provide support services from a commercial viewpoint, targeted toward scalable exosome manufacturing and analysis from potential diagnostic samples such as blood, urine, and saliva.
“The urine source segment accounted for the largest share in the exosome diagnostics and therapeutics market in 2023.”
Rapid commercialization of urine sample-based diagnostic tests is set to drive market. Urinary exosomes, released by cells in the urine system, represent an emerging route for diagnosing and monitoring renal disorders. Their distinct characteristics, such as the capacity to shield their molecular cargo from degradation and contamination, make them primary candidates for renal dysfunction and structural injury biomarkers. The non-invasive method of urine collection and the stability and sufficiency of urinary exosomes highlight its potential for early disease detection and diagnosis.
“Cancer is expected to emerge as the dominant application segment in the exosome therapeutics market.”
Growing focus on oncology therapeutics is expected to propel the market growth. Exosomes also play a critical role in cancer therapy as carriers of therapeutic cargo, delivering drugs, RNA interference molecules, or immunomodulatory agents to target cancer cells. The University of Texas MD Anderson Cancer Center in Texas (US) is conducting clinical trials (NCT03608631) to study the optimal dosage effects and effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation. Despite these developments, challenges such as optimizing the exosome isolation technology and ensuring efficient delivery of therapeutic cargo to tumors are expected to hinder market growth during the forecast period.
North America dominates the global exosome diagnostics and therapeutics market throughout the forecast period.
The exosome diagnostics and therapeutics market is segmented into four regions: North America, Europe, the Asia Pacific (APAC), and the Rest of the World. As of April 2024, only one exosome-based diagnostic product has been approved and is available in the US. The US has thus emerged as a key revenue source for the global exosome diagnostics and therapeutics market, in turn making North America the dominant region in the market.
Breakdown of supply-side primary interviews by company type, designation, and region:
- By Respondent: Supply Side (70%), Demand side (30%)
- By Designation: C-level (55%), Director-level (20%), and Others (25%)
- By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)
- Bio-Techne (US)
- NanoFCM Inc. (UK)
- System Biosciences, LLC. (US)
- Capital Biosciences, Inc. (US)
- AMSBIO (UK)
- INOVIQ (Australia)
- Direct Biologics LLC (US)
- Regeneus Ltd (Australia)
- CUREXSYS (Germany)
- Aegle Therapeutics (US)
- Mercy Bioanalytics (US)
- multimmune GmbH (Germany)
- RION (US)
- Exogenus Therapeutics (Portugal)
- Everzom (France)
- Kimera Labs (US)
- NanoSomiX, Inc. (US)
- Exonox Biosciences, Inc. (Taiwan)
- Capricor Therapeutics, Inc. (US)
- Evox Therapeutics (US)
- ILIAS Biologics Inc. (Korea)
This report studies the exosome diagnostics and therapeutics market based on type, product & service, source, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total exosome diagnostics and therapeutics market. The report forecasts the revenue of the market segments with respect to four major regions.
Reasons to Buy the Report:
The report provides insights on the following pointers:
.
- Market Drivers: The key factors driving the overall market growth emerging potential of exosome-based liquid biopsy, increasing collaborations & commercialization initiatives, and growing outsourcing of exosome manufacturing activities.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the exosome diagnostics and therapeutics market.
- Market Penetration: Comprehensive information on exosome diagnostics and therapeutics offered by the top 21 players in the market. The report analyzes the exosome diagnostics and therapeutics market by type, product & service, application, source, end user, and region.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/types of exosome diagnostics and therapeutics across key geographic regions.
- Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the exosome diagnostics and therapeutics market
- Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the exosome diagnostics and therapeutics market
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 MARKET SEGMENTATION
1.3.2 REGIONS COVERED
FIGURE 2 REGIONAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 3 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 4 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
FIGURE 9 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4 DATA TRIANGULATION AND MARKET BREAKDOWN
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ASSESSMENT ANALYSIS
TABLE 1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: RISK IMPACT ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
TABLE 3 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 4 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION)
FIGURE 12 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY PRODUCT & SERVICE, 2029 VS. 2032 (USD MILLION)
FIGURE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2029 VS. 2032 (USD MILLION)
FIGURE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY APPLICATION, 2029 VS. 2032 (USD MILLION)
FIGURE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2029 VS. 2032 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET
4 PREMIUM INSIGHTS
4.1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET OVERVIEW
FIGURE 17 EMERGING POTENTIAL OF EXOSOME-BASED LIQUID BIOPSY TO DRIVE MARKET
4.2 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE AND COUNTRY (2029)
FIGURE 18 EXOSOME THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2029
4.3 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION)
FIGURE 19 EXOSOME DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 EXOSOME DIAGNOSTICS AND THERAPEUTIC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Emerging potential of exosome-based liquid biopsy
5.2.1.2 Increasing initiatives for product commercialization
5.2.1.3 Growing outsourcing of exosome-based manufacturing activities
5.2.2 RESTRAINTS
5.2.2.1 Technical complexities associated with exosome isolation
5.2.2.2 Stringent regulatory requirements
5.2.3 OPPORTUNITIES
5.2.3.1 Growing adoption of exosome biomarkers for personalized medicine
5.2.4 CHALLENGES
5.2.4.1 Inadequate protocols for exosome development & production
5.3 SUPPLY CHAIN ANALYSIS
FIGURE 21 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS: MANUFACTURING PROCESSES AND REGULATORY INVESTMENTS ADD MAXIMUM VALUE
5.5 PATENT ANALYSIS
5.5.1 PATENT ANALYSIS: EXOSOME DIAGNOSTICS
FIGURE 23 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, JANUARY 2013–OCTOBER 2023
FIGURE 24 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, BY JURISDICTION
5.5.2 PATENT ANALYSIS: EXOSOME THERAPEUTICS
FIGURE 25 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, JANUARY 2013–OCTOBER 2023
FIGURE 26 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, BY JURISDICTION
5.6 REGULATORY LANDSCAPE
5.6.1 REGULATORY SCENARIO
5.6.1.1 North America
5.6.1.1.1 US
5.6.1.1.2 Canada
5.6.1.2 Europe
5.6.1.2.1 Germany
5.6.1.2.2 Spain
5.6.1.3 Asia Pacific
5.6.1.3.1 China
5.6.1.3.2 Japan
5.6.1.3.3 South Korea
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 PORTER’S FIVE FORCES ANALYSIS
TABLE 7 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF SUPPLIERS
5.7.4 BARGAINING POWER OF BUYERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EXOSOME DIAGNOSTICS & THERAPEUTICS
5.8.2 BUYING CRITERIA FOR END USERS
FIGURE 28 KEY BUYING CRITERIA FOR END USERS
5.9 INVESTMENT AND FUNDING SCENARIO
TABLE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: INVESTMENT & FUNDING SCENARIO
5.10 EXOSOME THERAPEUTICS: DEVELOPMENT & MANUFACTURING PROCESS
5.10.1 EXOSOME ISOLATION
TABLE 9 EXOSOME ISOLATION TECHNIQUES
5.10.2 EXOSOME CHARACTERIZATION AND QC
5.10.3 EXOSOME PRODUCTION
5.11 PIPELINE ANALYSIS
FIGURE 29 EXOSOME PIPELINE, BY INTERVENTION TYPE
FIGURE 30 EXOSOME PIPELINE, BY PHASE
5.11.1 PIPELINE ANALYSIS: EXOSOME THERAPEUTICS
FIGURE 31 EXOSOME THERAPEUTICS PIPELINE, BY PHASE
FIGURE 32 EXOSOME THERAPEUTICS PIPELINE, BY REGION
5.11.2 PIPELINE ANALYSIS: EXOSOME DIAGNOSTICS
FIGURE 33 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY APPLICATION
FIGURE 34 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY COUNTRY
TABLE 10 PIPELINE PRODUCTS FOR EXOSOME DIAGNOSTICS
TABLE 11 PIPELINE PRODUCTS FOR EXOSOME THERAPEUTICS
5.12 PRICING ANALYSIS
5.12.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
TABLE 12 AVERAGE SELLING PRICE OF EXOSOME DIAGNOSTIC PRODUCTS, BY KEY PLAYER
5.12.2 AVERAGE SELLING PRICE TREND, BY REGION
5.13 ECOSYSTEM ANALYSIS
FIGURE 35 EXOSOME DIAGNOSTICS AND THERAPEUTICS: ECOSYSTEM MAP
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 36 REVENUE SHIFT AND NEW POCKETS
5.15 KEY CONFERENCES & EVENTS
TABLE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2024–2025)
5.16 TECHNOLOGY ANALYSIS
5.16.1 KEY TECHNOLOGIES
TABLE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: KEY TECHNOLOGIES
5.16.2 COMPLIMENTARY TECHNOLOGIES
5.16.3 ADJACENT TECHNOLOGIES
6 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 16 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
6.2 EXOSOME DIAGNOSTICS
6.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION & DIAGNOSIS TO PROPEL MARKET
TABLE 17 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 18 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
TABLE 19 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 20 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 21 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 22 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 23 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 24 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
6.3 EXOSOME THERAPEUTICS
6.3.1 INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH
TABLE 25 EXOSOME THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 26 EXOSOME THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
TABLE 27 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 28 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 29 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 31 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
7 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
7.1 INTRODUCTION
TABLE 33 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 34 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2030–2032 (USD MILLION)
7.2 KITS & REAGENTS
7.2.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTIC KITS TO DRIVE MARKET
TABLE 35 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 36 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2030–2032 (USD MILLION)
TABLE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 39 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 40 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 41 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
7.3 INSTRUMENTS & SERVICES
7.3.1 RISING FOCUS ON OUTSOURCING EXOSOME PREPARATION ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 43 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 44 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2030–2032 (USD MILLION)
8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE
8.1 INTRODUCTION
TABLE 45 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 46 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
8.2 STEM CELLS
8.2.1 GROWING UPTAKE OF MSC-DERIVED EXOSOMES IN CELLULAR PROCESSES TO DRIVE MARKET
TABLE 47 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2022–2029 (USD MILLION)
TABLE 48 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2030–2032 (USD MILLION)
TABLE 49 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 50 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 51 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 52 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 53 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
8.3 BLOOD & BLOOD PLASMA
8.3.1 ABILITY TO ENHANCE TREATMENT RESPONSE AND DISEASE DIAGNOSIS TO BOOST DEMAND
TABLE 55 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2022–2029 (USD MILLION)
TABLE 56 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2030–2032 (USD MILLION)
TABLE 57 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 59 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 60 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 61 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 62 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
8.4 URINE
8.4.1 RAPID COMMERCIALIZATION OF URINE SAMPLE-BASED DIAGNOSTIC TESTS TO DRIVE MARKET
TABLE 63 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2022–2029 (USD MILLION)
TABLE 64 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2030–2032 (USD MILLION)
TABLE 65 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 67 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 68 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 69 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
8.5 OTHER SAMPLES
TABLE 71 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022–2029 (USD MILLION)
TABLE 72 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2030–2032 (USD MILLION)
TABLE 73 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 75 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 77 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 78 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
9 EXOSOME THERAPEUTICS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 79 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 80 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
9.2 CANCER
9.2.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET
TABLE 81 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
TABLE 82 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2030–2032 (USD MILLION)
TABLE 83 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 84 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 85 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 87 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
9.3 DERMATOLOGICAL DISEASES
9.3.1 INCREASING R&D ACTIVITIES FOR WOUND HEALING AND REGENERATIVE MEDICINE TO DRIVE MARKET
TABLE 89 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 90 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2030–2032 (USD MILLION)
TABLE 91 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 93 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 94 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 95 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
9.4 MUSCULOSKELETAL DISORDERS
9.4.1 RISING INCIDENCE OF OSTEOARTHRITIS TO SUPPORT MARKET GROWTH
TABLE 97 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 98 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2030–2032 (USD MILLION)
TABLE 99 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 101 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 103 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
9.5 CARDIOVASCULAR DISEASES
9.5.1 GROWING FOCUS ON TARGETED THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH
TABLE 105 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 106 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2030–2032 (USD MILLION)
TABLE 107 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 109 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 110 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 111 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 113 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 114 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2030–2032 (USD MILLION)
TABLE 115 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 116 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 117 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 119 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 120 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
10 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 121 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 122 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
10.2 HOSPITALS
10.2.1 GROWING COLLABORATIONS WITH PHARMA & BIOPHARMA COMPANIES TO DRIVE MARKET
TABLE 123 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
TABLE 124 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2030–2032 (USD MILLION)
TABLE 125 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 127 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 128 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 129 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
10.3 CLINICS AND PHYSICIAN SETTINGS
10.3.1 RISING ADOPTION OF LIQUID BIOPSY KITS TO SUPPORT MARKET GROWTH
TABLE 131 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2022–2029 (USD MILLION)
TABLE 132 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2030–2032 (USD MILLION)
TABLE 133 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 134 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 135 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 136 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 137 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 139 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 140 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT
TABLE 141 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 143 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 144 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 145 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 146 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 147 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 148 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 149 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 150 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.2.2 US
11.2.2.1 Rising R&D initiatives for development of exosomes to drive market
TABLE 151 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 152 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 153 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 154 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 155 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 156 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 157 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 158 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increasing funding initiatives for genomic-based treatments to support market growth
TABLE 159 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 161 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 162 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 163 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 164 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 165 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 166 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
FIGURE 38 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT
TABLE 167 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 168 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 169 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 171 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 172 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 173 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 174 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 175 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 176 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 Commercialization of pipeline candidates to propel market
TABLE 177 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 179 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 180 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 181 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 182 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 183 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 184 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.3 UK
11.3.3.1 Rising growth in life sciences research to drive market
TABLE 185 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 186 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 187 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 188 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 189 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 190 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 191 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 192 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Presence of emerging players for exosome preparation to fuel market
TABLE 193 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 194 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 195 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 196 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 197 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 198 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 199 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 200 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Rising growth in biotech sector to boost demand
TABLE 201 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 202 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 203 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 204 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 205 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 206 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 207 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 208 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Increasing initiatives for exosome research to support market growth
TABLE 209 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 211 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 212 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 213 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 214 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 215 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 216 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 217 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 218 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 219 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 220 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 221 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 222 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 223 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 224 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 MARKET SEGMENTATION
1.3.2 REGIONS COVERED
FIGURE 2 REGIONAL SEGMENTATION
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 3 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 4 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
2.2.1 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.3 MARKET GROWTH RATE PROJECTIONS
FIGURE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET (SUPPLY-SIDE): CAGR PROJECTIONS
FIGURE 9 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4 DATA TRIANGULATION AND MARKET BREAKDOWN
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ASSESSMENT ANALYSIS
TABLE 1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: RISK IMPACT ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 2 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH)
TABLE 3 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 4 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION)
FIGURE 12 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY PRODUCT & SERVICE, 2029 VS. 2032 (USD MILLION)
FIGURE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2029 VS. 2032 (USD MILLION)
FIGURE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY APPLICATION, 2029 VS. 2032 (USD MILLION)
FIGURE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2029 VS. 2032 (USD MILLION)
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET
4 PREMIUM INSIGHTS
4.1 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET OVERVIEW
FIGURE 17 EMERGING POTENTIAL OF EXOSOME-BASED LIQUID BIOPSY TO DRIVE MARKET
4.2 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE AND COUNTRY (2029)
FIGURE 18 EXOSOME THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2029
4.3 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2029 VS. 2032 (USD MILLION)
FIGURE 19 EXOSOME DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 EXOSOME DIAGNOSTICS AND THERAPEUTIC MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 5 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Emerging potential of exosome-based liquid biopsy
5.2.1.2 Increasing initiatives for product commercialization
5.2.1.3 Growing outsourcing of exosome-based manufacturing activities
5.2.2 RESTRAINTS
5.2.2.1 Technical complexities associated with exosome isolation
5.2.2.2 Stringent regulatory requirements
5.2.3 OPPORTUNITIES
5.2.3.1 Growing adoption of exosome biomarkers for personalized medicine
5.2.4 CHALLENGES
5.2.4.1 Inadequate protocols for exosome development & production
5.3 SUPPLY CHAIN ANALYSIS
FIGURE 21 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS
5.4 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS: MANUFACTURING PROCESSES AND REGULATORY INVESTMENTS ADD MAXIMUM VALUE
5.5 PATENT ANALYSIS
5.5.1 PATENT ANALYSIS: EXOSOME DIAGNOSTICS
FIGURE 23 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, JANUARY 2013–OCTOBER 2023
FIGURE 24 PATENT APPLICATIONS FOR EXOSOME DIAGNOSTICS, BY JURISDICTION
5.5.2 PATENT ANALYSIS: EXOSOME THERAPEUTICS
FIGURE 25 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, JANUARY 2013–OCTOBER 2023
FIGURE 26 PATENT APPLICATIONS FOR EXOSOME THERAPEUTICS, BY JURISDICTION
5.6 REGULATORY LANDSCAPE
5.6.1 REGULATORY SCENARIO
5.6.1.1 North America
5.6.1.1.1 US
5.6.1.1.2 Canada
5.6.1.2 Europe
5.6.1.2.1 Germany
5.6.1.2.2 Spain
5.6.1.3 Asia Pacific
5.6.1.3.1 China
5.6.1.3.2 Japan
5.6.1.3.3 South Korea
5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7 PORTER’S FIVE FORCES ANALYSIS
TABLE 7 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF SUPPLIERS
5.7.4 BARGAINING POWER OF BUYERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF EXOSOME DIAGNOSTICS & THERAPEUTICS
5.8.2 BUYING CRITERIA FOR END USERS
FIGURE 28 KEY BUYING CRITERIA FOR END USERS
5.9 INVESTMENT AND FUNDING SCENARIO
TABLE 8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: INVESTMENT & FUNDING SCENARIO
5.10 EXOSOME THERAPEUTICS: DEVELOPMENT & MANUFACTURING PROCESS
5.10.1 EXOSOME ISOLATION
TABLE 9 EXOSOME ISOLATION TECHNIQUES
5.10.2 EXOSOME CHARACTERIZATION AND QC
5.10.3 EXOSOME PRODUCTION
5.11 PIPELINE ANALYSIS
FIGURE 29 EXOSOME PIPELINE, BY INTERVENTION TYPE
FIGURE 30 EXOSOME PIPELINE, BY PHASE
5.11.1 PIPELINE ANALYSIS: EXOSOME THERAPEUTICS
FIGURE 31 EXOSOME THERAPEUTICS PIPELINE, BY PHASE
FIGURE 32 EXOSOME THERAPEUTICS PIPELINE, BY REGION
5.11.2 PIPELINE ANALYSIS: EXOSOME DIAGNOSTICS
FIGURE 33 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY APPLICATION
FIGURE 34 EXOSOME DIAGNOSTIC TESTS PIPELINE, BY COUNTRY
TABLE 10 PIPELINE PRODUCTS FOR EXOSOME DIAGNOSTICS
TABLE 11 PIPELINE PRODUCTS FOR EXOSOME THERAPEUTICS
5.12 PRICING ANALYSIS
5.12.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
TABLE 12 AVERAGE SELLING PRICE OF EXOSOME DIAGNOSTIC PRODUCTS, BY KEY PLAYER
5.12.2 AVERAGE SELLING PRICE TREND, BY REGION
5.13 ECOSYSTEM ANALYSIS
FIGURE 35 EXOSOME DIAGNOSTICS AND THERAPEUTICS: ECOSYSTEM MAP
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 36 REVENUE SHIFT AND NEW POCKETS
5.15 KEY CONFERENCES & EVENTS
TABLE 13 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2024–2025)
5.16 TECHNOLOGY ANALYSIS
5.16.1 KEY TECHNOLOGIES
TABLE 14 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET: KEY TECHNOLOGIES
5.16.2 COMPLIMENTARY TECHNOLOGIES
5.16.3 ADJACENT TECHNOLOGIES
6 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 15 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 16 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
6.2 EXOSOME DIAGNOSTICS
6.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION & DIAGNOSIS TO PROPEL MARKET
TABLE 17 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 18 EXOSOME DIAGNOSTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
TABLE 19 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 20 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 21 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 22 EUROPE: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 23 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 24 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
6.3 EXOSOME THERAPEUTICS
6.3.1 INCREASING NUMBER OF CLINICAL TRIALS TO SUPPORT MARKET GROWTH
TABLE 25 EXOSOME THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 26 EXOSOME THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
TABLE 27 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 28 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 29 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 EUROPE: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 31 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 32 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
7 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
7.1 INTRODUCTION
TABLE 33 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
TABLE 34 EXOSOME DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2030–2032 (USD MILLION)
7.2 KITS & REAGENTS
7.2.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTIC KITS TO DRIVE MARKET
TABLE 35 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2022–2029 (USD MILLION)
TABLE 36 EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY REGION, 2030–2032 (USD MILLION)
TABLE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 38 NORTH AMERICA: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 39 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 40 EUROPE: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 41 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 ASIA PACIFIC: EXOSOME DIAGNOSTICS MARKET FOR KITS & REAGENTS, BY COUNTRY, 2030–2032 (USD MILLION)
7.3 INSTRUMENTS & SERVICES
7.3.1 RISING FOCUS ON OUTSOURCING EXOSOME PREPARATION ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 43 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 44 EXOSOME DIAGNOSTICS MARKET FOR INSTRUMENTS & SERVICES, BY REGION, 2030–2032 (USD MILLION)
8 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE
8.1 INTRODUCTION
TABLE 45 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 46 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
8.2 STEM CELLS
8.2.1 GROWING UPTAKE OF MSC-DERIVED EXOSOMES IN CELLULAR PROCESSES TO DRIVE MARKET
TABLE 47 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2022–2029 (USD MILLION)
TABLE 48 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY REGION, 2030–2032 (USD MILLION)
TABLE 49 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 50 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 51 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 52 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 53 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR STEM CELLS, BY COUNTRY, 2030–2032 (USD MILLION)
8.3 BLOOD & BLOOD PLASMA
8.3.1 ABILITY TO ENHANCE TREATMENT RESPONSE AND DISEASE DIAGNOSIS TO BOOST DEMAND
TABLE 55 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2022–2029 (USD MILLION)
TABLE 56 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY REGION, 2030–2032 (USD MILLION)
TABLE 57 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 58 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 59 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 60 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 61 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 62 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR BLOOD & BLOOD PLASMA, BY COUNTRY, 2030–2032 (USD MILLION)
8.4 URINE
8.4.1 RAPID COMMERCIALIZATION OF URINE SAMPLE-BASED DIAGNOSTIC TESTS TO DRIVE MARKET
TABLE 63 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2022–2029 (USD MILLION)
TABLE 64 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY REGION, 2030–2032 (USD MILLION)
TABLE 65 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 66 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 67 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 68 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 69 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR URINE, BY COUNTRY, 2030–2032 (USD MILLION)
8.5 OTHER SAMPLES
TABLE 71 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022–2029 (USD MILLION)
TABLE 72 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY REGION, 2030–2032 (USD MILLION)
TABLE 73 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 75 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 77 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 78 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2030–2032 (USD MILLION)
9 EXOSOME THERAPEUTICS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 79 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 80 EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
9.2 CANCER
9.2.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET
TABLE 81 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
TABLE 82 EXOSOME THERAPEUTICS MARKET FOR CANCER, BY REGION, 2030–2032 (USD MILLION)
TABLE 83 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 84 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 85 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 86 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 87 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2030–2032 (USD MILLION)
9.3 DERMATOLOGICAL DISEASES
9.3.1 INCREASING R&D ACTIVITIES FOR WOUND HEALING AND REGENERATIVE MEDICINE TO DRIVE MARKET
TABLE 89 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 90 EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY REGION, 2030–2032 (USD MILLION)
TABLE 91 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 93 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 94 EUROPE: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 95 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
9.4 MUSCULOSKELETAL DISORDERS
9.4.1 RISING INCIDENCE OF OSTEOARTHRITIS TO SUPPORT MARKET GROWTH
TABLE 97 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 98 EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2030–2032 (USD MILLION)
TABLE 99 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 100 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 101 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 EUROPE: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 103 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 104 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2030–2032 (USD MILLION)
9.5 CARDIOVASCULAR DISEASES
9.5.1 GROWING FOCUS ON TARGETED THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH
TABLE 105 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 106 EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2030–2032 (USD MILLION)
TABLE 107 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 109 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 110 EUROPE: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 111 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2030–2032 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 113 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 114 EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2030–2032 (USD MILLION)
TABLE 115 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 116 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 117 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 119 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 120 ASIA PACIFIC: EXOSOME THERAPEUTICS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2030–2032 (USD MILLION)
10 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 121 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 122 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
10.2 HOSPITALS
10.2.1 GROWING COLLABORATIONS WITH PHARMA & BIOPHARMA COMPANIES TO DRIVE MARKET
TABLE 123 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION)
TABLE 124 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2030–2032 (USD MILLION)
TABLE 125 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 127 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 128 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 129 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 130 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2030–2032 (USD MILLION)
10.3 CLINICS AND PHYSICIAN SETTINGS
10.3.1 RISING ADOPTION OF LIQUID BIOPSY KITS TO SUPPORT MARKET GROWTH
TABLE 131 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2022–2029 (USD MILLION)
TABLE 132 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY REGION, 2030–2032 (USD MILLION)
TABLE 133 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 134 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 135 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 136 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 137 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET FOR CLINICS AND PHYSICIAN SETTINGS, BY COUNTRY, 2030–2032 (USD MILLION)
11 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 139 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 140 EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY REGION, 2030–2032 (USD MILLION)
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 37 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT
TABLE 141 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 142 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 143 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 144 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 145 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 146 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 147 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 148 NORTH AMERICA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 149 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 150 NORTH AMERICA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.2.2 US
11.2.2.1 Rising R&D initiatives for development of exosomes to drive market
TABLE 151 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 152 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 153 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 154 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 155 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 156 US: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 157 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 158 US: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.2.3 CANADA
11.2.3.1 Increasing funding initiatives for genomic-based treatments to support market growth
TABLE 159 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 161 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 162 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 163 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 164 CANADA: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 165 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 166 CANADA: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3 EUROPE
11.3.1 EUROPE: RECESSION IMPACT
FIGURE 38 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET SNAPSHOT
TABLE 167 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 168 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY COUNTRY, 2030–2032 (USD MILLION)
TABLE 169 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 171 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 172 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 173 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 174 EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 175 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 176 EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.2 GERMANY
11.3.2.1 Commercialization of pipeline candidates to propel market
TABLE 177 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 179 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 180 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 181 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 182 GERMANY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 183 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 184 GERMANY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.3 UK
11.3.3.1 Rising growth in life sciences research to drive market
TABLE 185 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 186 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 187 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 188 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 189 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 190 UK: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 191 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 192 UK: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.4 FRANCE
11.3.4.1 Presence of emerging players for exosome preparation to fuel market
TABLE 193 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 194 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 195 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 196 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 197 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 198 FRANCE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 199 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 200 FRANCE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.5 ITALY
11.3.5.1 Rising growth in biotech sector to boost demand
TABLE 201 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 202 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 203 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 204 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 205 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 206 ITALY: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 207 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 208 ITALY: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.6 SPAIN
11.3.6.1 Increasing initiatives for exosome research to support market growth
TABLE 209 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 211 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 212 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 213 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 214 SPAIN: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 215 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 216 SPAIN: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
11.3.7 REST OF EUROPE
TABLE 217 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 218 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY TYPE, 2030–2032 (USD MILLION)
TABLE 219 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION)
TABLE 220 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY SOURCE, 2030–2032 (USD MILLION)
TABLE 221 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 222 REST OF EUROPE: EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2030–2032 (USD MILLION)
TABLE 223 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 224 REST OF EUROPE: EXOSOME DIAGNOSTICS AND THERAPEUTICS MARKET, BY END USER, 2030–2032 (USD MILLION)
